Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression

Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells

(2015) Andrew G. Evans et al.   BRITISH JOURNAL OF HAEMATOLOGY

Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance and predict a poor prognosis in MCL patients independent of CCND1

(2015) A E Teo et al.   LEUKEMIA

p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression

(2014) Yi Xie et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

voom: precision weights unlock linear model analysis tools for RNA-seq read counts

(2014) Charity W Law et al.   GENOME BIOLOGY

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

(2012) Z. Y. Xu-Monette et al.   BLOOD

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

(2011) Bo Li et al.   BMC BIOINFORMATICS

Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma

(2011) Jana Smardova   INTERNATIONAL JOURNAL OF ONCOLOGY

p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors

(2009) T L Slatter et al.   CELL DEATH AND DIFFERENTIATION

CD19: a promising B cell target for rheumatoid arthritis

(2009) Thomas F. Tedder   Nature Reviews Rheumatology

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study

(2008) K. H. Young et al.   BLOOD